HYPEROXALURIA AND CALCIUM OXALATE CRYSTALLURIA, DEVELOPMENT MECHANISMS AND CORRECTION POSSIBILITIES
Article Sidebar
Это произведение доступно по лицензии Creative Commons «Attribution» («Атрибуция») 4.0 Всемирная.
Main Article Content
Аннотация:
The article presents modern ideas of hyperoxaluria and oxalate-calcium crystaluria. Oxalic acid metabolism is investigated in normal and the main risk factors for hyperoxalaturia are considered. The clinical symptoms and diagnosis of hyperoxalaturia and oxalate-calcium crystaluria in children are described. Author presents basic principles of correction including diet therapy, drinking regime, phytotherapy, medication
Article Details
Как цитировать:
Библиографические ссылки:
Averyanova N.I., Balueva L.G. Oxalate crystalluria in children. International Journal of Applied and Basic Research 2012; 5:25-27.
Averyanova N.I., Balueva L.G., Ivanova N.V., Rudavina T.I. Violation of the metabolism of oxalic acid in children. Electronic scientific journal: Modern problems of science and education 2015;3.
Bagdasarova I.V., Stoeva T.V., Zheltovskaya N.I. The study of clinical and laboratory features in dysmetabolic nephropathies in children.Perinatology and pediatrics, 2009; 3(39):71–73.
Voronina N.V., Gribovskaya N.V., Evseev A.N., Ezersky D.V. Peculiarities of urinary syndrome in patients with oxalate nephropathy in comparison with nephrobiopsy results. Far Eastern Medical Journal 2013;3:15-20.
Gavrilova V.A., Malkoch A.V. Dysmetabolic nephropathy. Attending physician 2006; 1:32–36.
Gordeeva E.A., Vrzhesinskaya O.A., Kodentsova V.M., Kharitonchik L.A., Alekseeva N.V., Dunaeva I.P. Pathogenetic role of vitamin B2 and B6 deficiency in the development of dysmetabolic nephropathies in children. Questions of modern pediatrics 2004; 6(3):32-34.
Gres A.A., Voshchula V.I., Rybina I.L., Shloma L.P. Urolithiasis: experience with the use and effectiveness of Kanefron. Medical News 2004;
Dlin V.V., Shatokhina O.V., Osmanov I.M., Yurieva E.A. Efficiency of Kanefron® N in children with dysmetabolic nephropathy with oxalate-calcium crystalluria. Bulletin of Pediatric Pharmacology and Nutrition 2008; 4(5):66-69.
Dlin V.V., Ignatova M.S. , Morozov S.L., Yurieva E.A., Osmanov I.M. Dysmetabolic nephropathy in children. Russian Bulletin of Perinatology and Pediatrics 2012; 5(57):36-44.
Dlin V.V., Osmanov I.M. Dysmetabolic nephropathy with oxalate-calcium crystalluria. Effective pharmacotherapy 2013; 42:8-26
Zverev Ya.F., Zharikov A.Yu., Bryukhanov V.M., Lampatov V.V. Modulators of oxalate nephrolithiasis. crystallization inhibitors. Nephrology 2010; 1(14):29-49.
Zubarenko A.V., Stoeva T.V. Dysmetabolic nephropathy in pediatric practice. Message 1. Principles of diagnostics. Health child 2009; 4(19):132–136.
Zubarenko A.V., Stoeva T.V. Dysmetabolic nephropathy in pediatric practice. International Journal of Pediatrics, Obstetrics and Gynecology Traven/Cherven 2016 Volume 9 No. 3 Message 2. Principles of treatment and prevention. Child Health 2011; 3(30):97-104.
Ignatova O.A., Markova V.I., Menshikova L.I., Tyukova N.V. Connective tissue dysplasia in children with oxalate nephropathies. Ros.pediatric journal 2003; 6:29-31.
Kazakova K.E., Kondratieva E.I., Terent'eva A.A., Sukhanova G.A. Experience in the rehabilitation of children with dysmetabolic nephropathies living in an industrial city. Questions of modern pediatrics 2009; 1(8):41-45.
Guidelines on Urolithiasis European (EAU, 2013) (abridged) Association of Urology 2013/ Kidney Journal 2013; 4(06):44-54.
Rychkova S.V. .Dysmetabolic nephropathy in pediatric practice. Attending Physician 2010;8:11-15.
Smirnova I.S., Ignatova O.A. Risk factors for the development of secondary oxaluria in children. Literature review. Human Ecology 2009; 11:57-62.
Sukalo A.V., Shevchenko O.S. The use of Canephron N in dysmetabolic nephropathies in children. Recipe: scientific and practical magazine for pharmacists and doctors 2009; 1(63):106-110.
Bаttino B.S., DeFoor W., Coe F., Tackett L., Erhard M., Wacksman J. et al. Metabolic evaluation of children with urolithiasis: are adult references for supersaturation appropriate? J Urol. 2002;168:2568–71.
Gambardella R., Richardson R. The pathmays of oxalate formation from phenylalanine, tryptophan and ascorbic acid in the rat. Biochim. Biophys. Acta 1977; 499:156–168.
Kaufman D.W., Kelly J.P. , Curhan G.C., Anderson T.E. , Dretler S.P., Preminger G.M. et al. Oxalobacter formigenes May Reduce the Risk of Calcium Oxalate Kidney Stones. J Am Soc Nephrol. 2008 Jun; 19(6):1197–1203.
Lyon E.S., Borden T.A., Ellis J.E., Vermeulen C.W. Calcium oxalate lithiasis produced by pyridoxine deficiency and inhibition with high magnesium diets. Invest Urol. 1966 Sep; 4(2):133-142.
Massey L.K., Liebman M., Kynast-Gales S.A. Ascorbate increases human oxaluria and kidney stone risk. J Nutr. 2005 Jul;135(7):1673-1677.
Naber K.G. Efficacy and safety of the phytotherapeutic drug Canephron® N in prevention and treatment of urogenital and gestational disease: review of clinical experience in Eastern Europe and Central Asia. Res Rep Urol.2013 Feb4;5:39-46.
Nicoletta J., Lande M. Medical evaluation and treatment of urolithiasis. Pediatr Clin North Am 2006; 53:479-491.
Williams H.E. Oxalic acid and the hyperoxaluric syndromes. Kidney Intern. 1978; 13:410-417.